Does LRMR pay dividends?

Larimar Therapeutics Inc (LRMR) does not currently pay a regular dividend.

What is LRMR's market cap?

Larimar Therapeutics Inc (LRMR) has a market capitalization of $396.83M with a current stock price of $3.82.

Larimar Therapeutics Inc (LRMR)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.82

-0.19 (-4.74%)

Market Cap: $396.83M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

70%(28/40)

Avg Surprise

+7.85%

Streak

2 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.35

Range$-0.37 - $-0.31

7 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.45-28.4%

60d ago$-0.43-23.3%

30d ago$-0.42-20.8%

7d ago$-0.42-20.8%

Current$-0.35

Revenue Consensus

Range$0 - $0

11 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.05

Range$-0.19 - $0.16

7 analysts

Revenue Consensus

Range$0 - $0

11 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.05	$-0.19 - $0.16	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.35	$-0.37 - $-0.31	-	-	7	6 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 4, 2026Reported Aug 4	$-0.30	$-0.39	$-0.48 - $-0.33	+23.08%	Beat	8	1 0 30d	+26.8%
Mar 31, 2026Mar 26 Reported May 14, 2026Reported May 14	$-0.31	$-0.59	$-0.74 - $-0.40	+47.46%	Beat	5	0 3 30d	+32.6%
Dec 31, 2025Dec 25 Reported Mar 19, 2026Reported Mar 19	$-0.73	$-0.49	$-0.67 - $-0.41	-48.98%	Miss	7	0 3 30d	-62.2%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.61	$-0.39	$-0.50 - $-0.36	-56.41%	Miss	8	6 1 30d	-154.2%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-0.41	$-0.49	$-0.51 - $-0.46	+16.33%	Beat	7	1 0 30d	-20.6%
Mar 31, 2025Mar 25 Reported Apr 30, 2025Reported Apr 30	$-0.46	$-0.41	$-0.46 - $-0.35	-12.20%	Miss	7	1 3 30d	-70.4%
Dec 31, 2024Dec 24 Reported Mar 24, 2025Reported Mar 24	$-0.45	$-0.32	$-0.45 - $-0.25	-40.89%	Miss	10	1 0 30d	-50.0%
Sep 30, 2024Sep 24 Reported Oct 30, 2024Reported Oct 30	$-0.24	$-0.37	$-0.42 - $-0.29	+35.14%	Beat	11	No revisions (30d)	-14.3%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-0.34	$-0.32	$-0.35 - $-0.26	-6.25%	Miss	6	No revisions (30d)	-78.9%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.27	$-0.24	$-0.25 - $-0.21	-12.50%	Miss	4	No revisions (30d)	-80.0%
Dec 31, 2023Dec 23 Reported Mar 14, 2024Reported Mar 14	$-0.30	$-0.25	$-0.28 - $-0.22	-20.00%	Miss	5	No revisions (30d)	-42.9%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.21	$-0.23	$-0.27 - $-0.20	+8.70%	Beat	5	No revisions (30d)	+43.2%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.19	$-0.21	$-0.27 - $-0.15	+9.52%	Beat	5	No revisions (30d)	+59.6%
Mar 31, 2023Mar 23 Reported May 15, 2023Reported May 15	$-0.15	$-0.25	$-0.26 - $-0.23	+40.00%	Beat	4	No revisions (30d)	+69.4%
Dec 31, 2022Dec 22 Reported Mar 14, 2023Reported Mar 14	$-0.21	$-0.37	$-0.78 - $-0.21	+43.24%	Beat	5	No revisions (30d)	+58.0%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.37	$-0.42	$-0.77 - $-0.20	+11.90%	Beat	4	No revisions (30d)	+59.8%
Jun 30, 2022Jun 22 Reported Aug 11, 2022Reported Aug 11	$-0.47	$-0.57	$-0.57 - $-0.57	+17.54%	Beat	0	No revisions (30d)	+40.5%
Mar 31, 2022Mar 22 Reported May 12, 2022Reported May 12	$-0.49	$-0.51	$-0.51 - $-0.51	+3.92%	Beat	2	No revisions (30d)	+35.5%
Dec 31, 2021Dec 21 Reported Mar 25, 2022Reported Mar 25	$-0.50	$-0.72	$-0.96 - $-0.43	+30.56%	Beat	3	No revisions (30d)	+43.8%
Sep 30, 2021Sep 21 Reported Nov 12, 2021Reported Nov 12	$-0.92	$-0.66	$-0.69 - $-0.60	-39.39%	Miss	3	1 0 30d	-43.8%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-0.79	$-0.75	$-0.78 - $-0.70	-5.33%	Miss	3	No revisions (30d)	+34.7%
Mar 31, 2021Mar 21 Reported May 10, 2021Reported May 10	$-0.76	$-0.86	$-0.93 - $-0.80	+11.63%	Beat	2	No revisions (30d)	+36.7%
Dec 31, 2020Dec 20 Reported Mar 4, 2021Reported Mar 4	$-0.89	$-0.70	-	-27.14%	Miss	2	No revisions (30d)	+61.0%
Sep 30, 2020Sep 20 Reported Nov 10, 2020Reported Nov 10	$-0.64	N/A	-	+71.93%	Beat	-	-	+77.8%
Jun 30, 2020Jun 20 Reported Aug 11, 2020Reported Aug 11	$-1.21	$-2.16	$-2.16 - $-2.16	+43.98%	Beat	0	No revisions (30d)	+68.5%
Mar 31, 2020Mar 20 Reported May 8, 2020Reported May 8	$-1.20	$-2.28	$-2.28 - $-2.28	+47.37%	Beat	0	No revisions (30d)	+71.4%
Dec 31, 2019Dec 19 Reported Mar 5, 2020Reported Mar 5	$-2.28	$-2.28	-	+0.00%	Beat	-	-	+51.3%
Sep 30, 2019Sep 19 Reported Nov 6, 2019Reported Nov 6	$-2.88	$-3.20	-	+10.00%	Beat	-	-	+41.5%
Jun 30, 2019Jun 19 Reported Aug 8, 2019Reported Aug 8	$-3.84	$-4.38	-	+12.33%	Beat	-	-	+43.9%
Mar 31, 2019Mar 19 Reported May 9, 2019Reported May 9	$-4.20	$-5.09	-	+17.49%	Beat	-	-	+39.7%
Dec 31, 2018Dec 18 Reported Mar 11, 2019Reported Mar 11	$-4.68	$-5.26	-	+11.03%	Beat	-	-	+18.8%
Sep 30, 2018Sep 18 Reported Nov 7, 2018Reported Nov 7	$-4.92	$-5.64	-	+12.77%	Beat	-	-	+10.9%
Jun 30, 2018Jun 18 Reported Aug 7, 2018Reported Aug 7	$-6.84	$-7.08	-	+3.39%	Beat	-	-	-16.3%
Mar 31, 2018Mar 18 Reported May 8, 2018Reported May 8	$-6.96	$-6.18	-	-12.62%	Miss	-	-	-20.8%
Dec 31, 2017Dec 17 Reported Mar 6, 2018Reported Mar 6	$-5.76	$-6.84	-	+15.79%	Beat	-	-	-26.3%
Sep 30, 2017Sep 17 Reported Nov 7, 2017Reported Nov 7	$-5.52	$-6.92	-	+20.23%	Beat	-	-	+14.8%
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-5.88	$-6.24	-	+5.77%	Beat	-	-	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$-5.76	$-5.21	-	-10.56%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Mar 9, 2017Reported Mar 9	$-4.56	$-6.03	-	+24.38%	Beat	-	-	-
Sep 30, 2016Sep 16 Reported Nov 9, 2016Reported Nov 9	$-6.48	$-7.28	-	+10.99%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.96	EV/EBITDA	-4.13x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-139.60%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	4.70x	Quick Ratio	4.70x
Trading Statistics
Beta	0.75	Avg Volume	1.05M
52-Week High	$6.42	52-Week Low	$2.71

Technical Indicators Dashboard

Moving Averages

SMA 10$4.09

SMA 20$4.16

SMA 50$3.88

SMA 200$3.92

EMA 10$4.06

EMA 20$4.07

EMA 50$3.97

EMA 200$3.87

MACD

Line: 0.03Signal: 0.08Hist: -0.05

ADX

ADX: 23.2+DI: 11.1-DI: 26.2

Aroon & PSAR

Aroon Up52.0

Aroon Down12.0

PSAR$4.35

Bollinger Bands

Upper Band$4.43

Lower Band$3.88

%B Position1316%(Upper)

Band Width-0.11

RSI (14-Day)

Neutral

42.3

Momentum Oscillators

Stoch %K13.0

Stoch %D25.7

Williams %R-98.5

ROC (10d)-11.6%

Momentum-0.50

CCI (20d)-209.2

MFI (14d)37.4

Volatility Measures

ATR (14d)$0.22(5.7%)

StdDev (20d)0.14

Hist Vol52.8%(High)

Volume Flow

VWAP$3.88

OBV136.6M

AD Line9.7M

CMF (20d)-0.067

Volume Metrics

Avg Vol (20d)1.1M

Vol Ratio1.0x

VWMA (20d)$4.17

Pivot Points

R3$4.17

R2$4.12

R1$4.07

Pivot Point$4.02

S1$3.97

S2$3.92

S3$3.87

Advanced Oscillators

TSI3.55

Ultimate Osc45.5

KST89.08

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$482,000	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	$87,000	$0	$0	$0	$241,000	$0	$0	$0	$81,000	$0
Gross Profit	$0	$0	$-87,000	$0	$0	$0	$241,000	$0	$0	$0	$-81,000	$0

Operating Expenses	$34.35M	$31.12M	$64.02M	$49.50M	$27.79M	$31.19M	$31.29M	$18.26M	$24.60M	$16.73M	$14.16M	$10.34M
R&D	$28.00M	$25.03M	$59.37M	$44.93M	$23.37M	$26.55M	$26.74M	$13.92M	$19.68M	$12.94M	$10.65M	$6.58M
SG&A	$6.35M	$6.09M	$4.64M	$4.57M	$4.42M	$4.64M	$4.55M	$4.34M	$4.92M	$3.79M	$3.51M	$3.75M
Operating Income	$-34,351,000	$-31,117,000	$-64,018,000	$-49,499,000	$-27,792,000	$-31,188,000	$-31,293,000	$-18,264,000	$-24,599,000	$-16,734,000	$-14,162,000	$-10,339,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$5.30M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-32,782,000	$-31,117,000	$-69,322,000	$-47,712,000	$-26,182,000	$-29,281,000	$-28,824,000	$-15,499,000	$-21,627,000	$-14,654,000	$-12,993,000	$-9,064,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-32,782,000	$-29,613,000	$-62,498,000	$-47,712,000	$-26,182,000	$-29,281,000	$-28,824,000	$-15,499,000	$-21,627,000	$-14,654,000	$-12,993,000	$-9,064,000

EBITDA	$-33,065,000	$-31,133,000	$-64,088,000	$-47,949,000	$-26,556,000	$-29,948,000	$-29,929,000	$-17,138,000	$-23,318,000	$-15,157,000	$-13,545,000	$-9,553,000
EBIT	$-32,782,000	$-31,117,000	$-64,018,000	$-47,712,000	$-26,182,000	$-29,281,000	$-28,824,000	$-15,499,000	$-21,627,000	$-14,654,000	$-12,993,000	$-9,064,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about LRMR

News

Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR

Hennion & Walsh Asset Management Inc. has acquired a new position in Larimar Therapeutics, Inc. (NASDAQ:LRMR), purchasing 396,726 shares valued at approximately $1.21 million. This makes them a 0.38% owner of the company, with institutional investors collectively holding 91.92% of the stock. Insider activity also includes Director Thomas Edward Hamilton's purchase of 50,000 shares, increasing his holdings by 7.52%.

MarketBeat•Aug 13, 2026 9:41 AM8/13/26•

Bullish

Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR

Dimensional Fund Advisors LP significantly increased its stake in Larimar Therapeutics (NASDAQ:LRMR) by 143.8% in the first quarter, acquiring an additional 470,968 shares to own a total of 798,462 shares valued at approximately $3.6 million. Institutional investors now hold 91.92% of the company's stock. Larimar Therapeutics, a clinical-stage biotechnology company developing a treatment for Friedreich’s ataxia, has a consensus "Buy" rating and a target price of $12.57 from analysts, despite some recent target reductions.

MarketBeat•Aug 13, 2026 7:41 AM8/13/26•

Bullish

Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR

Renaissance Technologies LLC significantly increased its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 148.9% in the first quarter, now holding 739,942 shares valued at approximately $3.33 million. Institutional investors and hedge funds collectively own 91.92% of LRMR. Insider buying also occurred, with Director Thomas Edward Hamilton purchasing 50,000 shares, while analysts generally maintain a "Buy" rating with an average price target of $12.57.

MarketBeat•Aug 9, 2026 11:16 AM8/9/26•

Bullish

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Larimar Therapeutics (LRMR) faces substantial regulatory and manufacturing risks regarding its nomlabofusp drug, impacting its accelerated approval timeline. Delays in BLA submission or issues with third-party manufacturers could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street analysts maintain a Strong Buy consensus rating for LRMR stock.

The Globe and Mail•Aug 6, 2026 5:41 AM8/6/26•

Bearish

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

Larimar Therapeutics (LRMR) faces significant regulatory and manufacturing risks for its nomlabofusp drug, impacting its accelerated approval path. Delays in BLA submission or issues with third-party manufacturers, especially those with FDA Form 483 observations, could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street maintains a "Strong Buy" consensus rating on LRMR stock.

The Globe and Mail•Aug 6, 2026 1:10 AM8/6/26•

Bearish

Frequently Asked Questions About LRMR

Does LRMR pay dividends?: Larimar Therapeutics Inc (LRMR) does not currently pay a regular dividend.
What is LRMR's market cap?: Larimar Therapeutics Inc (LRMR) has a market capitalization of $396.83M with a current stock price of $3.82.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In